Photodynamic Therapy for Abscess
Trial Summary
What is the purpose of this trial?
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) standard of care abscess drainage. The primary endpoint is reduction in time to removal of the drainage catheter.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the treatment Methylene Blue Photodynamic Therapy for abscesses?
Research shows that photodynamic therapy (PDT) using methylene blue is effective in killing bacteria in abscesses and other infections, including drug-resistant ones. Studies have demonstrated that PDT can be tailored to individual patients, improving its effectiveness in treating abscess cavities.12345
How is methylene blue photodynamic therapy different from other treatments for abscesses?
Methylene blue photodynamic therapy (MB-PDT) is unique because it uses a special dye (methylene blue) and light to kill bacteria in abscesses, which is different from traditional methods like antibiotics or surgical drainage. This approach can target drug-resistant bacteria and is being explored for its effectiveness in deep tissue infections.12567
Research Team
Laurie Christensen, BS
Principal Investigator
University of Rochester
Ashwani K Sharma, MD
Principal Investigator
University of Rochester
Timothy M Baran, PhD
Principal Investigator
University of Rochester
Eligibility Criteria
Adults over 18 with symptoms, lab results, and scans indicating an abscess needing drainage can join. They must be approved by their care team for PDT treatment. Excluded are those with poor kidney function, pregnant or lactating individuals, low platelet counts, bleeding disorders, no safe access to the abscess, inability to consent or follow procedures, large abscesses (>13 cm), allergies to certain substances including contrast media and eggs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive methylene blue photodynamic therapy (MB-PDT) or standard of care abscess drainage
Follow-up
Participants are monitored for safety and effectiveness after treatment, including time to removal of the drainage catheter and symptom resolution
Long-term Follow-up
Participants are monitored for long-term abscess resolution and recurrence
Treatment Details
Interventions
- Methylene Blue Photodynamic Therapy
- Standard of care abscess drainage
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor